Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms.

Liisborg C, Hasselbalch HC, Sørensen TL.

Cancers (Basel). 2020 Mar 2;12(3). pii: E573. doi: 10.3390/cancers12030573. Review.

2.

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group.

Lancet Haematol. 2020 Mar;7(3):e196-e208. doi: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31. Erratum in: Lancet Haematol. 2020 Feb 25;:.

PMID:
32014125
3.

Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms.

Pedersen RK, Andersen M, Knudsen TA, Sajid Z, Gudmand-Hoeyer J, Dam MJB, Skov V, Kjaer L, Ellervik C, Larsen TS, Hansen D, Pallisgaard N, Hasselbalch HC, Ottesen JT.

Cancer Med. 2020 Mar;9(6):2039-2051. doi: 10.1002/cam4.2741. Epub 2020 Jan 28.

4.

Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer.

Holmström MO, Cordua S, Skov V, Kjær L, Pallisgaard N, Ellervik C, Hasselbalch HC, Andersen MH.

Cancer Immunol Immunother. 2020 Feb;69(2):315-324. doi: 10.1007/s00262-019-02473-y. Epub 2020 Jan 8. Review.

PMID:
31915854
5.

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.

Sørensen AL, Mikkelsen SU, Knudsen TA, Bjørn ME, Andersen CL, Bjerrum OW, Brochmann N, Patel DA, Gjerdrum LMR, El Fassi D, Kruse TA, Larsen TS, Mourits-Andersen HT, Nielsen CH, Ellervik C, Pallisgaard N, Thomassen M, Kjær L, Skov V, Hasselbalch HC.

Haematologica. 2019 Dec 26. pii: haematol.2019.235648. doi: 10.3324/haematol.2019.235648. [Epub ahead of print]

6.

Smoking, blood cells and myeloproliferative neoplasms: meta-analysis and Mendelian randomization of 2·3 million people.

Jayasuriya NA, Kjaergaard AD, Pedersen KM, Sørensen AL, Bak M, Larsen MK, Nordestgaard BG, Bojesen SE, Çolak Y, Skov V, Kjaer L, Tolstrup JS, Hasselbalch HC, Ellervik C.

Br J Haematol. 2019 Dec 25. doi: 10.1111/bjh.16321. [Epub ahead of print]

PMID:
31875952
7.

Vascular Diseases In Patients With Chronic Myeloproliferative Neoplasms - Impact Of Comorbidity.

Frederiksen H, Szépligeti S, Bak M, Ghanima W, Hasselbalch HC, Christiansen CF.

Clin Epidemiol. 2019 Nov 1;11:955-967. doi: 10.2147/CLEP.S216787. eCollection 2019.

8.

Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?

Hasselbalch HC.

Haematologica. 2019 Nov;104(11):2119-2125. doi: 10.3324/haematol.2019.229039. No abstract available.

9.

[Therapeutic cancer vaccination for treatment of haematological cancers].

Holmström MO, Grauslund JH, Dahlager-Jørgensen NG, Klausen U, Hasselbalch HC, Andersen MH.

Ugeskr Laeger. 2019 Oct 14;181(20A). pii: V04190233. Danish.

PMID:
31610839
10.

The red blood cell count and the erythrocyte sedimentation rate in the diagnosis of polycythaemia vera.

Nersesjan V, Zervides KA, Sørensen AL, Kjaer L, Skov V, Hasselbalch HC.

Eur J Haematol. 2020 Jan;104(1):46-54. doi: 10.1111/ejh.13334. Epub 2019 Nov 22.

PMID:
31584701
11.

Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat.

McPherson S, Greenfield G, Andersen C, Grinfeld J, Hasselbalch HC, Nangalia J, Mills KI, McMullin MF.

Exp Hematol. 2019 Nov;79:26-34. doi: 10.1016/j.exphem.2019.09.025. Epub 2019 Sep 26.

12.

Association of the blood eosinophil count with end-organ symptoms.

Bjerrum OW, Siersma V, Hasselbalch HC, Lind B, Andersen CL.

Ann Med Surg (Lond). 2019 Jul 9;45:11-18. doi: 10.1016/j.amsu.2019.06.015. eCollection 2019 Sep.

13.

B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment.

Sørensen AL, Bjørn ME, Riley CH, Holmstrøm M, Andersen MH, Svane IM, Mikkelsen SU, Skov V, Kjaer L, Hasselbalch HC, Nielsen CH.

Eur J Haematol. 2019 Oct;103(4):351-361. doi: 10.1111/ejh.13292. Epub 2019 Aug 18.

PMID:
31297883
14.

Progression of JAK2-mutant polycythemia vera to CALR-mutant myelofibrosis severely impacts on disease phenotype and response to therapy.

Holmström MO, Novotny GW, Petersen J, Aaboe-Jørgensen M, Hasselbalch HC, Andersen MH, Nielsen SL, Fassi DE, Schöllkopf C.

Leuk Lymphoma. 2019 Dec;60(13):3296-3299. doi: 10.1080/10428194.2019.1633634. Epub 2019 Jul 1. No abstract available.

PMID:
31256699
15.

Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population.

Cordua S, Kjaer L, Skov V, Pallisgaard N, Hasselbalch HC, Ellervik C.

Blood. 2019 Aug 1;134(5):469-479. doi: 10.1182/blood.2019001113. Epub 2019 Jun 19. Erratum in: Blood. 2019 Oct 3;134(14):1195.

PMID:
31217187
16.

Neo-antigen specific memory T-cell responses in healthy individuals.

Holmström MO, Hasselbalch HC, Andersen MH.

Oncoimmunology. 2019 Apr 19;8(7):1599640. doi: 10.1080/2162402X.2019.1599640. eCollection 2019.

PMID:
31143522
17.

[Cancer immune therapy for the treatment of haematological malignancies].

Holmström MO, Klausen U, Jørgensen NG, Holmberg S, Grauslund J, Met Ö, Svane IM, Pedersen LM, Knudsen LM, Hasselbalch HC, Andersen MH.

Ugeskr Laeger. 2019 Mar 4;181(10). pii: V06180421. Danish.

PMID:
30869069
18.

Smoking and Increased White and Red Blood Cells.

Pedersen KM, Çolak Y, Ellervik C, Hasselbalch HC, Bojesen SE, Nordestgaard BG.

Arterioscler Thromb Vasc Biol. 2019 May;39(5):965-977. doi: 10.1161/ATVBAHA.118.312338.

PMID:
30866659
19.

Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis.

Bjørn ME, Brimnes MK, Gudbrandsdottir S, Andersen CL, Poulsen HE, Henriksen T, Hasselbalch HC, Nielsen CH.

Leuk Lymphoma. 2019 Oct;60(10):2549-2557. doi: 10.1080/10428194.2019.1579323. Epub 2019 Feb 20.

PMID:
30785365
20.

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.

Holmström MO, Ahmad SM, Klausen U, Bendtsen SK, Martinenaite E, Riley CH, Svane IM, Kjær L, Skov V, Ellervik C, Pallisgaard N, Hasselbalch HC, Andersen MH.

Blood Cancer J. 2019 Jan 17;9(2):8. doi: 10.1038/s41408-018-0166-4.

21.

Bridging blood cancers and inflammation: The reduced Cancitis model.

Ottesen JT, Pedersen RK, Sajid Z, Gudmand-Hoeyer J, Bangsgaard KO, Skov V, Kjær L, Knudsen TA, Pallisgaard N, Hasselbalch HC, Andersen M.

J Theor Biol. 2019 Mar 21;465:90-108. doi: 10.1016/j.jtbi.2019.01.001. Epub 2019 Jan 4.

PMID:
30615883
22.

Statin treatment, oxidative stress and inflammation in a Danish population.

Sørensen AL, Hasselbalch HC, Nielsen CH, Poulsen HE, Ellervik C.

Redox Biol. 2019 Feb;21:101088. doi: 10.1016/j.redox.2018.101088. Epub 2018 Dec 21.

23.

Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark.

Brochmann N, Flachs EM, Christensen AI, Bak M, Andersen CL, Juel K, Hasselbalch HC, Zwisler AD, Rottmann N.

Clin Epidemiol. 2018 Dec 18;11:23-33. doi: 10.2147/CLEP.S162688. eCollection 2019.

24.

JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation.

Czech J, Cordua S, Weinbergerova B, Baumeister J, Crepcia A, Han L, Maié T, Costa IG, Denecke B, Maurer A, Schubert C, Feldberg K, Gezer D, Brümmendorf TH, Müller-Newen G, Mayer J, Racil Z, Kubesova B, Knudsen T, Sørensen AL, Holmström M, Kjær L, Skov V, Larsen TS, Hasselbalch HC, Chatain N, Koschmieder S.

Leukemia. 2019 Apr;33(4):995-1010. doi: 10.1038/s41375-018-0295-6. Epub 2018 Nov 23.

PMID:
30470838
25.

Publisher Correction: Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations.

Nielsen HM, Andersen CL, Westman M, Kristensen LS, Asmar F, Kruse TA, Thomassen M, Larsen TS, Skov V, Hansen LL, Bjerrum OW, Hasselbalch HC, Punj V, Grønbæk K.

Sci Rep. 2018 Nov 20;8(1):17311. doi: 10.1038/s41598-018-35596-w.

26.

Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study.

Pedersen KM, Bak M, Sørensen AL, Zwisler AD, Ellervik C, Larsen MK, Hasselbalch HC, Tolstrup JS.

Cancer Med. 2018 Nov;7(11):5796-5802. doi: 10.1002/cam4.1815. Epub 2018 Oct 14.

27.

Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, Godfrey AL, Papaemmanuil E, Gundem G, MacLean C, Cook J, O'Neil L, O'Meara S, Teague JW, Butler AP, Massie CE, Williams N, Nice FL, Andersen CL, Hasselbalch HC, Guglielmelli P, McMullin MF, Vannucchi AM, Harrison CN, Gerstung M, Green AR, Campbell PJ.

N Engl J Med. 2018 Oct 11;379(15):1416-1430. doi: 10.1056/NEJMoa1716614.

28.

Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation.

Jørgensen MA, Holmström MO, Martinenaite E, Riley CH, Hasselbalch HC, Andersen MH.

Oncoimmunology. 2018 Jul 23;7(9):e1468957. doi: 10.1080/2162402X.2018.1468957. eCollection 2018.

29.

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?

Hasselbalch HC, Holmström MO.

Semin Immunopathol. 2019 Jan;41(1):5-19. doi: 10.1007/s00281-018-0700-2. Epub 2018 Sep 10. Review.

30.

Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis?

Elbæk MV, Sørensen AL, Hasselbalch HC.

Ann Hematol. 2019 Jan;98(1):101-109. doi: 10.1007/s00277-018-3489-0. Epub 2018 Sep 4.

PMID:
30182347
31.

Cancer immune therapy for myeloid malignancies: present and future.

Holmström MO, Hasselbalch HC.

Semin Immunopathol. 2019 Jan;41(1):97-109. doi: 10.1007/s00281-018-0693-x. Epub 2018 Jul 9. Review.

PMID:
29987478
32.

Whole Blood Gene Expression Profiling in patients undergoing colon cancer surgery identifies differential expression of genes involved in immune surveillance, inflammation and carcinogenesis.

Watt SK, Hasselbalch HC, Skov V, Kjær L, Thomassen M, Kruse TA, Burton M, Gögenur I.

Surg Oncol. 2018 Jun;27(2):208-215. doi: 10.1016/j.suronc.2018.03.002. Epub 2018 Mar 27.

PMID:
29937173
33.

Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.

Mikkelsen SU, Kjaer L, Bjørn ME, Knudsen TA, Sørensen AL, Andersen CBL, Bjerrum OW, Brochmann N, Fassi DE, Kruse TA, Larsen TS, Mourits-Andersen HT, Nielsen CH, Pallisgaard N, Thomassen M, Skov V, Hasselbalch HC.

Cancer Med. 2018 Aug;7(8):3571-3581. doi: 10.1002/cam4.1619. Epub 2018 Jun 22.

34.

The effectiveness of exercise-based rehabilitation to patients with myeloproliferative neoplasms-An explorative study.

Pedersen KM, Zangger G, Brochmann N, Grønfeldt BM, Zwisler AD, Hasselbalch HC, Tang LH.

Eur J Cancer Care (Engl). 2018 Sep;27(5):e12865. doi: 10.1111/ecc.12865. Epub 2018 Jun 11.

PMID:
29888803
35.

Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response.

Holmström MO, Riley CH, Skov V, Svane IM, Hasselbalch HC, Andersen MH.

Oncoimmunology. 2018 Feb 27;7(6):e1433521. doi: 10.1080/2162402X.2018.1433521. eCollection 2018.

36.

Myeloproliferative Neoplasms in Danish Twins.

Andersen MA, Bjerrum OW, Ranjan A, Skov V, Kruse TA, Thomassen M, Skytthe A, Hasselbalch HC, Christensen K.

Acta Haematol. 2018;139(3):195-198. doi: 10.1159/000488384. Epub 2018 May 2.

PMID:
29719285
37.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G.

Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Review.

38.

Associations between fatigue, physical activity, and QoL in patients with myeloproliferative neoplasms.

Tolstrup Larsen R, Tang LH, Brochmann N, Meulengracht Flachs E, Illemann Christensen A, Hasselbalch HC, Zwisler AD.

Eur J Haematol. 2018 Jun;100(6):550-559. doi: 10.1111/ejh.13048. Epub 2018 Apr 6.

PMID:
29464777
39.

Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry.

Herborg LL, Nederby L, Hasselbalch HC, Aggerholm A, Roug AS.

Int J Lab Hematol. 2018 Jun;40(3):320-325. doi: 10.1111/ijlh.12787. Epub 2018 Feb 10.

PMID:
29427319
40.

The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy.

Holmström MO, Hasselbalch HC, Andersen MH.

Oncoimmunology. 2017 Aug 2;6(11):e1358334. doi: 10.1080/2162402X.2017.1358334. eCollection 2017.

41.

Effects of rituximab and dexamethasone on regulatory and proinflammatory B-cell subsets in patients with primary immune thrombocytopenia.

Gudbrandsdottir S, Brimnes M, Køllgaard T, Hasselbalch HC, Nielsen CH.

Eur J Haematol. 2018 Jan;100(1):45-52. doi: 10.1111/ejh.12978. Epub 2017 Oct 18.

PMID:
28960473
42.

Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development.

Andersen M, Sajid Z, Pedersen RK, Gudmand-Hoeyer J, Ellervik C, Skov V, Kjær L, Pallisgaard N, Kruse TA, Thomassen M, Troelsen J, Hasselbalch HC, Ottesen JT.

PLoS One. 2017 Aug 31;12(8):e0183620. doi: 10.1371/journal.pone.0183620. eCollection 2017.

43.

Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes.

Kjaer L, Holmström MO, Cordua S, Andersen MH, Svane IM, Thomassen M, Kruse TA, Pallisgaard N, Skov V, Hasselbalch HC.

Leuk Lymphoma. 2018 Apr;59(4):973-977. doi: 10.1080/10428194.2017.1359743. Epub 2017 Aug 9. No abstract available.

PMID:
28792253
44.

Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations.

Nielsen HM, Andersen CL, Westman M, Kristensen LS, Asmar F, Kruse TA, Thomassen M, Larsen TS, Skov V, Hansen LL, Bjerrum OW, Hasselbalch HC, Punj V, Grønbæk K.

Sci Rep. 2017 Jul 28;7(1):6774. doi: 10.1038/s41598-017-07057-3. Erratum in: Sci Rep. 2018 Nov 20;8(1):17311.

45.

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.

Holmström MO, Martinenaite E, Ahmad SM, Met Ö, Friese C, Kjær L, Riley CH, Thor Straten P, Svane IM, Hasselbalch HC, Andersen MH.

Leukemia. 2018 Feb;32(2):429-437. doi: 10.1038/leu.2017.214. Epub 2017 Jul 5.

PMID:
28676668
46.

Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.

Bak M, Sørensen TL, Flachs EM, Zwisler AD, Juel K, Frederiksen H, Hasselbalch HC.

JAMA Ophthalmol. 2017 Aug 1;135(8):835-843. doi: 10.1001/jamaophthalmol.2017.2011.

47.

Molecular profiling as a novel tool to predict response to interferon-α2 in MPNs: The proof of concept in early myelofibrosis.

Hasselbalch HC.

Cancer. 2017 Jul 15;123(14):2600-2603. doi: 10.1002/cncr.30676. Epub 2017 May 18. No abstract available.

48.

Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.

Bjørn ME, Hasselbalch HC.

Expert Rev Hematol. 2017 May;10(5):393-404. doi: 10.1080/17474086.2017.1284583. Epub 2017 Apr 12. Review.

PMID:
28402197
49.

Anemia is present years before myelodysplastic syndrome diagnosis: Results from the pre-diagnostic period.

Hansen JW, Sandholdt H, Siersma V, Ørskov AD, Holmberg S, Bjerrum OW, Hasselbalch HC, Olivarius NF, Grønbaek K, Andersen CL.

Am J Hematol. 2017 Jul;92(7):E130-E132. doi: 10.1002/ajh.24757. Epub 2017 May 26. No abstract available.

50.

A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents.

Brochmann N, Flachs EM, Christensen AI, Andersen CL, Juel K, Hasselbalch HC, Zwisler AD.

Clin Epidemiol. 2017 Mar 2;9:141-150. doi: 10.2147/CLEP.S117587. eCollection 2017.

Supplemental Content

Loading ...
Support Center